New drug tested to shield cancer patients from Chemotherapy's Blood-Thinning danger
NCT ID NCT07252375
Summary
This study is testing whether a drug called hetrombopag can prevent a serious side effect of chemotherapy for nasopharyngeal (nose and throat) cancer. The side effect, called thrombocytopenia, is when platelet counts drop too low, raising the risk of dangerous bleeding. The study will enroll 35 patients who are receiving a specific chemotherapy and who had low platelets in their last treatment cycle, to see if hetrombopag can prevent it from happening again.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.